Comparative Pharmacology
Head-to-head clinical analysis: ORAGRAFIN SODIUM versus RENOVIST II.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ORAGRAFIN SODIUM versus RENOVIST II.
ORAGRAFIN SODIUM vs RENOVIST II
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Oragrafin Sodium is an oral cholecystographic contrast agent containing sodium ipodate. It is absorbed orally, excreted by the liver into bile, and concentrates in the gallbladder, allowing radiographic visualization. The iodine atoms in the molecule absorb X-rays, providing contrast. It also inhibits thyroid hormone synthesis by blocking iodine organification and may be used in amiodarone-induced thyrotoxicosis.
RENOVIST II is a radiographic contrast agent that contains diatrizoate meglumine and diatrizoate sodium. It increases the radiopacity of vascular structures and organs by attenuating X-rays due to the high atomic number of iodine atoms in the molecule.
Oral: 50-60 mL of a 10% solution (5-6 g sodium iopodate) as a single dose 10-12 hours before cholecystography. Repeat if needed: 50 mL (5 g) the next evening. Intravenous: Not applicable (oral agent).
1-2 mL/kg IV bolus, not to exceed 150 mL total; may be repeated once if necessary.
None Documented
None Documented
Terminal elimination half-life is approximately 60-90 minutes in patients with normal renal function (creatinine clearance > 90 mL/min), reflecting rapid renal clearance of this water-soluble contrast agent.
1.2 hours in patients with normal renal function; prolonged to 8–12 hours in severe renal impairment (CrCl <30 mL/min).
Primarily renal (hepatic/biliary/fecal: minimal). Approximately 80-90% of the absorbed dose is excreted unchanged in urine via glomerular filtration; <10% eliminated in feces via biliary excretion.
Renal: 95% as unchanged drug via glomerular filtration; fecal: <5%.
Category C
Category C
Radiocontrast Agent
Radiocontrast Agent